^(131)I-抗CEA单抗防治大肠癌根治术后肝转移的实验研究

Experimental study in the prevention and therapy of liver metastases after curative resection of colorectal cancer with ^(131)I (anti CEA)MoAb

目的 探讨1 3 1 I 抗癌胚抗原 (CEA)单抗防治裸鼠体内人结肠癌细胞肝转移的效果。方法 裸鼠脾内注入人结肠癌细胞后、脾切除后第 4或第 8d腹腔注射1 3 1 I 抗CEA单抗 ,观察术后生存时间 ,并对肝脏进行组织学检查。结果 术后第 4或第 8d注射1 3 1 I 抗CEA单抗均显著延长裸鼠术后生存时间 ;术后第 4d注射可使肝转移率减少 33 3% ,第 8d注射不能使肝转移率减少。结论 术后早期行放射免疫治疗可取得较好的治疗效果 。

Objective To investigate the effect of 131 I (anti CEA)MoAb for treatment of human colon cancer cells (HCCC) liver metastases in nude mice Methods We gave intraperitioneal injection of 131 I (anti CEA)MoAb on the 4th or the 8th day after intrasplenic injection of HCCC and subsequent splenectomy, then we observed the postoperative survial time of the nude mice and examined the livers pathologically Results The 131 I (anti CEA)MoAb injected on the 4th or the 8th postoperative day could significantly prolong the postoperative survival time The incidence of liver metastases was decreased by 33 3% with the injection of 131 I (anti CEA)MoAb on the 4th postoperative day but not on the 8th postoperative day Conclusions The study indicates that the early employment of the radioimmunotherapy may be more efficacious for the containment of HCCC liver metastases and this therapy is especially suitable for the treatment of hepatic micrometastases